

# WSC Congress

One world voice for stroke

**DATE: 22-24 OCTOBER 2025**

**Location:** Barcelona, Spain

## Rapid genetic testing for personalised antiplatelet therapy

Our Genedrive® CYP2C19 ID Kit



**6 ALLELES**  
Ethnically diverse coverage



**REAGENTS**  
Shipped and stored at room temperature



**INTEGRATED**  
All you need in one compact device



**EASE-OF-USE**  
1 buccal swab for the test



**RESULTS**  
Diplotype and Metaboliser status



**CONNECTIVITY**  
Result can be stored in Electronic Health Record

Join the **Genedrive team on STAND 17** to hear how our rapid point-of-care CYP2C19 genetic test aids in **secondary stroke prevention** by providing the information needed to determine **the most effective clinical pathway**.

To arrange a meeting contact [enquires@genedrive.com](mailto:enquires@genedrive.com)

Register here for  
**WSC 2025**



For more information scan the QR CODE

### Intellectual Property

Genedrive® is a registered trademark of Genedrive Diagnostics Ltd. Copyright © 2025 genedrive plc. All rights reserved. GPM-189 October 2025

“The point of care test of choice for CYP2C19 genotyping for patients with Ischemic stroke or TIA.”

“A precision medicine approach based on CYP2C19 genetic testing is recommended.”

Recommended by National Institute for Health and Care Excellence (NICE)

As recommended by American Heart Association (AHA)